[go: up one dir, main page]

MA47573A - Inhibiteurs de dihydrobenzofurane glycosidase substitués - Google Patents

Inhibiteurs de dihydrobenzofurane glycosidase substitués

Info

Publication number
MA47573A
MA47573A MA047573A MA47573A MA47573A MA 47573 A MA47573 A MA 47573A MA 047573 A MA047573 A MA 047573A MA 47573 A MA47573 A MA 47573A MA 47573 A MA47573 A MA 47573A
Authority
MA
Morocco
Prior art keywords
dihydrobenzofurane
substituted
glycosidase inhibitors
glycosidase
inhibitors
Prior art date
Application number
MA047573A
Other languages
English (en)
Inventor
Awadut Gajendra Giri
Santosh S Kulkarni
Anna Quattropani
Original Assignee
Asceneuron S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/054268 external-priority patent/WO2017144633A1/fr
Application filed by Asceneuron S A filed Critical Asceneuron S A
Publication of MA47573A publication Critical patent/MA47573A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA047573A 2016-02-25 2017-08-24 Inhibiteurs de dihydrobenzofurane glycosidase substitués MA47573A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621006643 2016-02-25
PCT/EP2017/054268 WO2017144633A1 (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases
PCT/EP2017/054280 WO2017144639A1 (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases

Publications (1)

Publication Number Publication Date
MA47573A true MA47573A (fr) 2021-04-28

Family

ID=58159077

Family Applications (3)

Application Number Title Priority Date Filing Date
MA043680A MA43680A (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases
MA047573A MA47573A (fr) 2016-02-25 2017-08-24 Inhibiteurs de dihydrobenzofurane glycosidase substitués
MA047574A MA47574A (fr) 2016-02-25 2017-08-24 Inhibiteurs de la sulfoximine glycosidase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA043680A MA43680A (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA047574A MA47574A (fr) 2016-02-25 2017-08-24 Inhibiteurs de la sulfoximine glycosidase

Country Status (11)

Country Link
US (2) US10556902B2 (fr)
EP (1) EP3419972B1 (fr)
JP (1) JP2019506430A (fr)
KR (3) KR20180132626A (fr)
CN (1) CN108884078A (fr)
AU (1) AU2017222964B2 (fr)
CA (2) CA3012624A1 (fr)
IL (1) IL268501A (fr)
MA (3) MA43680A (fr)
MX (1) MX2018010191A (fr)
WO (1) WO2017144639A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
WO2018153508A2 (fr) * 2017-02-24 2018-08-30 Asceneuron S.A. Inhibiteurs de la sulfoximine glycosidase
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
MX381953B (es) 2016-02-25 2025-03-13 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
US11612599B2 (en) * 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN110300752A (zh) 2016-12-16 2019-10-01 詹森药业有限公司 单环oga抑制剂化合物
CA3045745A1 (fr) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga
EP3672959A1 (fr) 2017-08-24 2020-07-01 Asceneuron SA Inhibiteurs linéaires de la glycosidase
TWI726329B (zh) * 2018-06-22 2021-05-01 美商美國禮來大藥廠 2,3-二氫呋喃并[2,3-b]吡啶化合物
CA3108158C (fr) 2018-07-31 2023-05-16 Eli Lilly And Company Composes 5-methyl-4-fluoro-thiazol-2-yl
CN113166083A (zh) * 2018-08-22 2021-07-23 阿森纽荣股份公司 用作糖苷酶抑制剂的哌嗪衍生物的琥珀酸盐和富马酸盐酸加成盐
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039028A1 (fr) * 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
WO2021123291A1 (fr) * 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2024083820A1 (fr) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Méthode et composition pour déterminer le niveau de o-glcnacylation chez des chevaux

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1311316A (fr) 1961-04-12 1962-12-07 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
NL127996C (fr) 1963-11-19
US3485757A (en) 1964-11-23 1969-12-23 Atomic Energy Commission Thermoelectric composition comprising doped bismuth telluride,silicon and boron
DE1595923A1 (de) 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
GB1165283A (en) 1967-01-17 1969-09-24 Science Union & Cie New Purine Derivatives and processes for prepararing them
US4600025A (en) 1982-11-18 1986-07-15 Grigg Ronald E Smoking products comprising nicotine substitutes
JPH07505648A (ja) 1992-04-15 1995-06-22 メルク　シヤープ　エンド　ドーム　リミテツド アザサイクリック化合物
IL118768A (en) 1995-07-12 2000-10-31 Akzo Nobel Nv Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU6852898A (en) 1997-04-17 1998-11-11 Takeda Chemical Industries Ltd. Thermogenic composition and benzazepine thermogenics
WO1999021850A1 (fr) 1997-10-24 1999-05-06 Neurogen Corporation Piperazines de 1-(2-naphtyle) et de 1-(2-azanaphtyle)-4-(1-phenylmethyle)en tant que ligands pour le sous-type du recepteur de la dopamine d¿4?
EP1389189A2 (fr) * 2001-05-22 2004-02-18 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de 1-benzyl-4-aryl piperazine substituee
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
MXPA04012440A (es) 2002-06-12 2005-04-28 Abbott Lab Antagonistas de receptor de hormona concentradora de melanina.
EP1531815B1 (fr) 2002-06-27 2014-09-24 Novo Nordisk A/S Activateurs de la glycokinase
DE60330456D1 (de) 2002-07-05 2010-01-21 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
CA2518839A1 (fr) 2003-04-18 2004-11-04 Eli Lilly And Company Composes (piperidinyloxy)phenyle, (piperidinyloxy)pyridinyle, (piperidinylsulfanyl)phenyle et (piperidinylsulfanyl)pyridinyle utilises comme agonistes des recepteurs 5-ht<sb>1f</sb>
CA2526374A1 (fr) 2003-05-21 2004-12-02 Banyu Pharmaceutical Co., Ltd. Derive de 2-aminoquinolines
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
US7253168B2 (en) 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
CA2819464A1 (fr) 2005-03-01 2006-09-08 Matthew Macauley Inhibiteurs selectifs de glycosidase, methodes de fabrication d'inhibiteurs et leurs utilisations
WO2007006760A1 (fr) 2005-07-08 2007-01-18 Novo Nordisk A/S Activateurs de dicycloalkylurée glucokinase
US20090192169A1 (en) 2006-03-31 2009-07-30 Ian Egle Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
EP2029593A1 (fr) 2006-05-22 2009-03-04 AstraZeneca AB Dérivés de l'indole
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
WO2008012623A1 (fr) 2006-07-25 2008-01-31 Pfizer Products Inc. Composés de benzimidazolyle constituant des potentialisateurs du sous-type de récepteur de glutamate mglur2
EP2057171A4 (fr) 2006-08-31 2010-04-21 Univ Fraser Simon Inhibiteurs sélectifs de glycosidases et leurs utilisations
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
WO2009011904A1 (fr) 2007-07-19 2009-01-22 Renovis, Inc. Composés utiles comme modulateurs de la faah et utilisation de ceux-ci
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
EP2276736A1 (fr) 2008-04-17 2011-01-26 Pfizer Inc. Composés aryl carboxamides à 5 éléments de 4-[3-(aryloxy)benzylidèn]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
CA2719784A1 (fr) 2008-04-17 2009-10-22 Pfizer Inc. Composes d'ether-benzylidene-piperidine-aryl a 5 chainons-carboxamide utiles comme inhibiteurs de faah
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
WO2010021381A1 (fr) 2008-08-22 2010-02-25 武田薬品工業株式会社 Dérivé hétérocyclique fusionné et son utilisation
WO2010022517A1 (fr) 2008-08-29 2010-03-04 Saint Mary's University Utilisation de gluconacetobacter et utilisation réduite d'engrais azoté pour améliorer la production de betteraves
EP2336104A4 (fr) 2008-09-02 2012-01-25 Nissan Chemical Ind Ltd Dérivé halogénoalkylsulfonanilide ortho-substitué et herbicide
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
EA201171098A1 (ru) 2009-03-02 2012-04-30 Сертрис Фармасьютикалз, Инк. 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина
US20100240720A1 (en) 2009-03-20 2010-09-23 Burnham Institute For Medical Research Allosteric jnk inhibitors
WO2010108268A1 (fr) 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Composés hétérocycliques inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
JP2010270034A (ja) 2009-05-20 2010-12-02 Sumitomo Chemical Co Ltd アミド化合物並びにその植物病害防除用途
EP2445340B1 (fr) 2009-06-22 2016-05-18 Millennium Pharmaceuticals, Inc. Acides hydroxamiques substitués et leurs utilisations
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
JP2013537233A (ja) 2010-09-17 2013-09-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 脂肪酸合成酵素阻害剤
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2638052B1 (fr) 2010-11-08 2017-03-22 Alectos Therapeutics, Inc. Inhibiteurs sélectifs de glycosidase et utilisations de ceux-ci
WO2012061972A1 (fr) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Inhibiteurs sélectifs de la glycosidase et ses utilisations
CA2822493C (fr) 2010-12-23 2018-11-20 Merck Sharp & Dohme Corp. Inhibiteurs selectifs de glycosidases et leurs utilisations
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
WO2012124744A1 (fr) 2011-03-14 2012-09-20 大正製薬株式会社 Composé hétérocyclique condensé contenant de l'azote
HUE029390T2 (en) 2011-08-25 2017-02-28 Merck Patent Gmbh Pirano [3,2-d] [1,3] thiazole derivatives as glucosidase inhibitors
EP2773207B1 (fr) 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine
EP2882733B1 (fr) 2012-08-08 2017-04-26 Novartis Tiergesundheit AG Azines substitues comme pesticides
US9522883B2 (en) 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
ES2723883T3 (es) 2013-03-14 2019-09-03 Merck Patent Gmbh Inhibidores de glicosidasa
CN103435606A (zh) 2013-08-22 2013-12-11 中国药科大学 CDK2与GSK3β双重抑制剂及用途
ME02883B (fr) 2013-12-05 2018-04-20 Pfizer Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
EP2913330A1 (fr) 2014-02-27 2015-09-02 Laboratoire Biodim Dérivés condensés d'imidazole utiles comme produits pharmaceutiques
RU2659070C9 (ru) 2014-04-23 2018-08-24 Дарт Нейросайенс (Кайман) Лтд. ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
AU2016287478B2 (en) 2015-07-02 2021-10-21 Janssen Sciences Ireland Uc Antibacterial compounds
SG11201803605YA (en) 2015-11-02 2018-05-30 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
WO2017087858A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017091818A1 (fr) 2015-11-25 2017-06-01 Lieber Institute For Brain Development Méthodes et compositions d'inhibition de comt
DK3389658T3 (da) 2015-12-18 2021-01-11 Merck Sharp & Dohme Glycosidasehæmmere og anvendelser deraf
US11612599B2 (en) * 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
WO2018153508A2 (fr) 2017-02-24 2018-08-30 Asceneuron S.A. Inhibiteurs de la sulfoximine glycosidase
MX381953B (es) 2016-02-25 2025-03-13 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
EP3419974B1 (fr) 2016-02-25 2021-05-05 Asceneuron SA Procédé de séparation d'énantiomères de dérivés de pipérazine
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
WO2018026371A1 (fr) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc
CN110300752A (zh) 2016-12-16 2019-10-01 詹森药业有限公司 单环oga抑制剂化合物
JP2020503300A (ja) 2016-12-16 2020-01-30 ヤンセン ファーマシューティカ エヌ．ベー． 二環式ｏｇａ阻害剤化合物
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
CN110267961A (zh) 2017-02-06 2019-09-20 詹森药业有限公司 Oga抑制剂化合物
CA3045745A1 (fr) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga
AR111693A1 (es) 2017-05-25 2019-08-07 Lilly Co Eli Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga

Also Published As

Publication number Publication date
CA3012624A1 (fr) 2017-08-31
MA43680A (fr) 2018-11-28
BR112019017514A2 (pt) 2020-03-31
EP3419972A1 (fr) 2019-01-02
IL268501A (en) 2019-09-26
US20190388415A1 (en) 2019-12-26
JP2019506430A (ja) 2019-03-07
EP3419972B1 (fr) 2023-07-26
US20190055239A1 (en) 2019-02-21
WO2017144639A1 (fr) 2017-08-31
AU2017222964B2 (en) 2020-01-02
US10995090B2 (en) 2021-05-04
MA47574A (fr) 2020-01-01
KR20230026541A (ko) 2023-02-24
CA3053200C (fr) 2023-03-14
CA3053200A1 (fr) 2018-08-30
KR102620279B1 (ko) 2024-01-03
KR20180132626A (ko) 2018-12-12
CN108884078A (zh) 2018-11-23
MX2018010191A (es) 2019-05-20
US10556902B2 (en) 2020-02-11
AU2017222964A1 (en) 2018-08-02
KR20190118184A (ko) 2019-10-17

Similar Documents

Publication Publication Date Title
IL269196A (en) Novel inhibitors
MA47573A (fr) Inhibiteurs de dihydrobenzofurane glycosidase substitués
IL263586A (en) Inhibitors of the menin-mll interaction
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
MA43677A (fr) Inhibiteurs de glycosidases
MA53944A (fr) Inhibiteurs de la glycosidase
IL269812A (en) Ferroportin-inhibitor salts
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3436444T3 (da) Heterocyklisk forbindelse
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3442972T3 (da) Bromdomænehæmmere
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3498693T3 (da) Heterocyklisk forbindelse
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
DK3323269T3 (da) Målingsbaseret direkte adgangskonfiguration
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
EP3706747A4 (fr) Inhibiteurs de prmt5
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3303283A4 (fr) Inhibiteurs de fto
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3706742A4 (fr) Inhibiteurs de prmt5